| Biomarker ID | 809 |
| PMID | 22078333 |
| Year | 2012 |
| Biomarker | %p2PSA |
| Biomarker Basis | Concentration Based (pg/ml) |
| Biomolecule | Protein |
| Source | Blood |
| Subjects | Humans |
| Regulation | Upregulated with GS upgrading |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: OR: 2.514 (95% CI: 1.492–4.238); Multivariate: 3.036 (95% CI: 1.657–5.561); |
| Effect on Pathways | Pathways Include :-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Gleason sum upgrading from 6 to 7 |
| Type of Biomarker | Prognostic |
| Cohort | 350 patients with prostate cancer were chosen. (n= 187) ≤6 and (n=130) GS=7 |
| Senstivity | 91.9 % (95% CI: 84.7–96.4) |
| Specificity | 19.2 % (95% CI:10.9–30.1) |
| AUC | 0.67 |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | UniCel DxI800 Immunoassay System analyser (Beckman Coulter Inc., Brea, CA, USA) |
| Clinical | No |
| Remarks | Sensitivity, Specificity calculated at 3 different criterions |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3 |